Brief: MoonLake Immunotherapeutics Completes Patient Enrollment, Randomization Ahead Of Phase 2 Trial Of Nanobody Sonelokimab
02/02/2023 13:56
Feb 2 (Reuters) - MoonLake Immunotherapeutics MLTX.O :
* MOONLAKE IMMUNOTHERAPEUTICS COMPLETES PATIENT ENROLLMENT
AND
RANDOMIZATION AHEAD OF SCHEDULE IN A PHASE 2 TRIAL OF THE
NANOBODY® SONELOKIMAB IN MODERATE-TO-SEVERE HIDRADENITIS
SUPPURATIVA
Source text for Eikon: ID:nGNX7W0qhs
Further company coverage: MLTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial